WO2017053983A1 - Quantifying met protein for cancer treatment - Google Patents
Quantifying met protein for cancer treatment Download PDFInfo
- Publication number
- WO2017053983A1 WO2017053983A1 PCT/US2016/053804 US2016053804W WO2017053983A1 WO 2017053983 A1 WO2017053983 A1 WO 2017053983A1 US 2016053804 W US2016053804 W US 2016053804W WO 2017053983 A1 WO2017053983 A1 WO 2017053983A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- met
- peptide
- amol
- mass spectrometry
- reference level
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020187011642A KR20180067557A (en) | 2015-09-24 | 2016-09-26 | Quantification of Met Protein for Cancer Therapy |
EP16849880.6A EP3352859B1 (en) | 2015-09-24 | 2016-09-26 | Quantifying met protein for cancer treatment |
AU2016325715A AU2016325715B2 (en) | 2015-09-24 | 2016-09-26 | Quantifying Met protein for cancer treatment |
CA2999895A CA2999895A1 (en) | 2015-09-24 | 2016-09-26 | Quantifying met protein for cancer treatment |
JP2018515596A JP2018531234A (en) | 2015-09-24 | 2016-09-26 | Quantification of Met protein for cancer treatment |
IL258340A IL258340A (en) | 2015-09-24 | 2018-03-25 | Quantifying met protein for cancer treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562232234P | 2015-09-24 | 2015-09-24 | |
US62/232,234 | 2015-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017053983A1 true WO2017053983A1 (en) | 2017-03-30 |
Family
ID=58387430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/053804 WO2017053983A1 (en) | 2015-09-24 | 2016-09-26 | Quantifying met protein for cancer treatment |
Country Status (8)
Country | Link |
---|---|
US (1) | US10288616B2 (en) |
EP (1) | EP3352859B1 (en) |
JP (2) | JP2018531234A (en) |
KR (1) | KR20180067557A (en) |
AU (1) | AU2016325715B2 (en) |
CA (1) | CA2999895A1 (en) |
IL (1) | IL258340A (en) |
WO (1) | WO2017053983A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021532360A (en) * | 2018-08-08 | 2021-11-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Use of LC-MS / MS to quantify protein biomarkers |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102462097B1 (en) * | 2020-12-30 | 2022-11-02 | 국립암센터 | Triple quadrupole-based multiple reaction monitoring for clinical therapeutic response prediction in cancer |
CN112924610A (en) * | 2021-02-01 | 2021-06-08 | 上海交通大学 | Mass spectrum-based ROS absolute quantification method in living cells and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7473532B2 (en) | 2003-03-10 | 2009-01-06 | Expression Pathology, Inc. | Liquid tissue preparation from histopathologically processed biological samples, tissues and cells |
US7906301B2 (en) | 2005-05-25 | 2011-03-15 | Expression Pathology, Inc. | Multiplex method for increased proteomic coverage from histopathologically processed biological samples, tissues cells |
US20130092079A1 (en) * | 2004-03-09 | 2013-04-18 | Boston Scientific Scimed, Inc. | Coated Medical Device and Method for Manufacturing the Same |
US20140005282A1 (en) * | 2010-12-27 | 2014-01-02 | Expression Pathology, Inc. | Cmet protein srm/mrm assay |
US20140234329A1 (en) | 2007-02-16 | 2014-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of erbb3 and uses thereof |
WO2014146139A2 (en) * | 2013-03-15 | 2014-09-18 | Expression Pathology, Inc. | Srm assay to indicate cancer therapy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19732517A1 (en) * | 1997-07-29 | 1999-02-04 | Bergner Richard Gmbh Co | Process for producing a flush mandrel break at the setting head height on mandrel break blind rivets with remaining mandrel |
AU2010273319B2 (en) | 2009-07-15 | 2015-01-22 | Nestec S.A. | Drug selection for gastric cancer therapy using antibody-based arrays |
WO2011125458A1 (en) | 2010-04-02 | 2011-10-13 | 富士レビオ株式会社 | Marker for diagnosing effect of anticancer agent |
US20120089541A1 (en) * | 2010-08-31 | 2012-04-12 | Genentech, Inc. | Biomarkers and methods of treatment |
MX2014002762A (en) | 2011-09-09 | 2014-07-30 | Amgen Inc | Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients. |
CA2873632A1 (en) * | 2012-05-16 | 2013-11-21 | Expression Pathology, Inc. | Srm/mrm assay for subtyping lung histology |
-
2016
- 2016-09-26 JP JP2018515596A patent/JP2018531234A/en active Pending
- 2016-09-26 CA CA2999895A patent/CA2999895A1/en not_active Withdrawn
- 2016-09-26 KR KR1020187011642A patent/KR20180067557A/en active IP Right Grant
- 2016-09-26 US US15/276,686 patent/US10288616B2/en active Active
- 2016-09-26 EP EP16849880.6A patent/EP3352859B1/en active Active
- 2016-09-26 AU AU2016325715A patent/AU2016325715B2/en active Active
- 2016-09-26 WO PCT/US2016/053804 patent/WO2017053983A1/en active Application Filing
-
2018
- 2018-03-25 IL IL258340A patent/IL258340A/en unknown
-
2020
- 2020-05-11 JP JP2020083465A patent/JP2020143103A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7473532B2 (en) | 2003-03-10 | 2009-01-06 | Expression Pathology, Inc. | Liquid tissue preparation from histopathologically processed biological samples, tissues and cells |
US20130092079A1 (en) * | 2004-03-09 | 2013-04-18 | Boston Scientific Scimed, Inc. | Coated Medical Device and Method for Manufacturing the Same |
US7906301B2 (en) | 2005-05-25 | 2011-03-15 | Expression Pathology, Inc. | Multiplex method for increased proteomic coverage from histopathologically processed biological samples, tissues cells |
US8293485B2 (en) | 2005-05-25 | 2012-10-23 | Expression Pathology, Inc. | Multiplex liquid tissue™ method for increased proteomic coverage from histopathologically processed biological samples, tissues and cells |
US20140234329A1 (en) | 2007-02-16 | 2014-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of erbb3 and uses thereof |
US20140005282A1 (en) * | 2010-12-27 | 2014-01-02 | Expression Pathology, Inc. | Cmet protein srm/mrm assay |
US9372195B2 (en) | 2010-12-27 | 2016-06-21 | Expression Pathology, Inc. | cMET protein SRM/MRM assay |
WO2014146139A2 (en) * | 2013-03-15 | 2014-09-18 | Expression Pathology, Inc. | Srm assay to indicate cancer therapy |
Non-Patent Citations (3)
Title |
---|
CATENACCI ET AL.: "Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue", PLOS ONE., vol. 9, no. 7, 1 July 2014 (2014-07-01), pages 1 - 14, XP055163884 * |
GUO ET AL.: "Multidimensional identification of tissue biomarkers of gastric cancer", JOURNAL OF PROTEOME RESEARCH, vol. 11, no. 6, 7 May 2012 (2012-05-07), pages 3405 - 3413, XP055177417 * |
SHAH ET AL.: "Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMETNEGFR2 inhibitor, in patents with metastatic gastric cancer", PLOS ONE., vol. 8, no. 3, 14 March 2013 (2013-03-14), pages 1 - 9, XP055371557 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021532360A (en) * | 2018-08-08 | 2021-11-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Use of LC-MS / MS to quantify protein biomarkers |
JP7419340B2 (en) | 2018-08-08 | 2024-01-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Use of LC-MS/MS to quantify protein biomarkers |
Also Published As
Publication number | Publication date |
---|---|
EP3352859A4 (en) | 2019-04-10 |
IL258340A (en) | 2018-06-28 |
JP2018531234A (en) | 2018-10-25 |
US10288616B2 (en) | 2019-05-14 |
KR20180067557A (en) | 2018-06-20 |
CA2999895A1 (en) | 2017-03-30 |
AU2016325715A1 (en) | 2018-05-10 |
AU2016325715B2 (en) | 2019-04-04 |
EP3352859B1 (en) | 2020-09-23 |
EP3352859A1 (en) | 2018-08-01 |
US20170097354A1 (en) | 2017-04-06 |
JP2020143103A (en) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6524266B2 (en) | Quantification of Her2 protein for optimal cancer therapy | |
US9746477B2 (en) | Quantifying FR-α and GART proteins for optimal cancer therapy | |
US10537576B2 (en) | Methods for treating Her2-positive breast cancer | |
JP2020143103A (en) | Quantification of Met protein for cancer treatment | |
US20200171082A1 (en) | Quantifying slfn11 protein for optimal cancer therapy | |
US20200103411A1 (en) | Predicting Cancer Treatment Outcome With T-DM1 | |
JP2018531234A6 (en) | Quantification of Met protein for cancer treatment | |
WO2018102827A1 (en) | Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy | |
EP3524249B1 (en) | Quantifying mgmt protein for optimal cancer therapy of glioblastoma | |
US20200271654A1 (en) | Quantifying MGMT Protein For Optimal Cancer Therapy | |
WO2017127703A1 (en) | Quantifying kras for optimal cancer therapy | |
CA2987610A1 (en) | Quantifying her2 protein for optimal cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16849880 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2999895 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018515596 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 258340 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187011642 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016849880 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016325715 Country of ref document: AU Date of ref document: 20160926 Kind code of ref document: A |